A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Director Clinical Research - Benign Hematology

Biology & BiotechUpdated on Nov 13
Full-timeCambridge, MA, USA$255k - $345kIn-person

About the Job

Requirements

  • An MD with a strong research background, or an MD-PhD with strong clinical and/or research training demonstrated through research support and peer-reviewed publications.
  • At least 3 years of industry experience or equivalent clinical academic research experience.
  • Sound scientific and clinical judgment.
  • Familiarity with clinical research and clinical trials, including biostatistics and regulatory agency organization, guidelines, and practices.
  • Ability to present ideas effectively and document complex medical and clinical concepts in writing and orally.
  • History of critical thinking and problem solving, with sound judgment and a balanced, realistic understanding of issues.
  • Outstanding leadership and collaboration skills in a matrix environment.

Responsibilities

  • Serve as a subject matter expert for the relevant disease areas.
  • Provide strategic leadership and a clear voice for the clinical program.
  • Develop creative but realistic drug development approaches and lead clinical efforts toward global regulatory approvals.
  • Oversee trial conduct and safety.
  • Collaborate with Preclinical, Regulatory Affairs, and Medical Affairs to integrate product development plans.
  • Be accountable through Clinical Research and Operations for relevant timelines and deliverables.
  • Closely supervise major written deliverables, including regulatory submissions, original articles, and abstracts, as well as presentation materials.
  • Provide final review and sign-off for controlled documents, including protocols, investigator brochures, and informed consent forms.
  • Influence internal and external audiences in a high-impact, highly visible manner.

Desired Qualifications

  • Board certification or equivalent, or specialist training in hematology.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs